Natera’s Signatera Data: Advancements in Lung Cancer Profiling

As lung cancer continues to rank as the most commonly diagnosed cancer worldwide, the push for more precise, personalized diagnostics remains urgent. In that context, Natera, Inc.—a leader in cell-free DNA technology and precision medicine—will present new findings at the upcoming 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, underscoring the clinical promise of its Signatera™ molecular residual disease (MRD) test.

Among the highlights of the conference, which will be held September 6–9 in Barcelona, is an oral presentation showcasing the prognostic power of Signatera Genome in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study reveals that Signatera’s MRD detection following surgery offers significant insight into both recurrence-free and overall survival—making it a potentially transformative tool for guiding post-surgical decision-making.

The oral presentation—scheduled for September 7 and delivered by Dr. Gaston Becharano—will focus on the clinical performance of a whole genome-based, tumor-informed circulating tumor DNA (ctDNA) assay. The data are expected to highlight how Signatera can identify recurrence risk earlier and more accurately than traditional imaging or pathology alone, with the goal of informing more personalized post-operative care plans.

In addition to the oral session, two poster presentations will further explore the role of Signatera in real-world clinical applications. Dr. Daniel Rosas will present findings on September 8 detailing how personalized ctDNA testing is being used to monitor treatment outcomes in lung cancer, reflecting the shift toward dynamic and individualized disease tracking. On September 9, Dr. Ken Masuda will present data from the MRDSEEKER study (JCOG2111A), a prospective trial evaluating how MRD status correlates with long-term prognosis in NSCLC patients treated with curative intent.

Collectively, these presentations aim to validate the potential of MRD-guided strategies to reshape treatment pathways in lung cancer, a field where early recurrence detection can make the difference between timely intervention and missed opportunity. While imaging remains a cornerstone of post-treatment surveillance, ctDNA assays like Signatera offer a non-invasive, molecular-level window into residual disease activity—an advantage particularly valuable in a disease as biologically diverse as NSCLC.

The foundation of Natera’s approach lies in its tumor-informed, whole-genome sequencing technology, which allows for highly individualized assays calibrated to a patient's unique tumor signature. This customization enhances sensitivity in detecting even trace levels of ctDNA, offering clinicians earlier, actionable insights.

As Natera continues to build a growing portfolio of peer-reviewed evidence—now supported by over 300 publications—the company’s presence at WCLC highlights not just technological advancement but also clinical momentum. The integration of Signatera into care pathways for lung cancer could represent a critical step toward truly personalized oncology, where post-surgical monitoring and treatment planning are guided not just by tumor staging or histology, but by real-time molecular evidence of disease activity.

With these new data, Natera reinforces its mission to make personalized genetic testing and diagnostics part of standard care—bringing earlier, more targeted interventions into focus for patients facing one of the world’s most formidable malignancies.